The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better

The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better

The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of spine surgery 2017-01, Vol.11 (2), p.12
Hauptverfasser: Chu, Stacey, Chen, Nita, Dang, Alexis B C, Kuo, Alfred C, Dang, Alan B C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 12
container_title International journal of spine surgery
container_volume 11
creator Chu, Stacey
Chen, Nita
Dang, Alexis B C
Kuo, Alfred C
Dang, Alan B C
description The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p
doi_str_mv 10.14444/4012
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28765796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-3304783c62c9e220224bda0ae95d454d27ff5cafadf286e0b2c24e7b4dec7cd3</originalsourceid><addsrcrecordid>eNpVkFtLw0AQhRdRbKn9C7IvPkb3lsv6IGipF2j0ocHXZbOZtZEkW3ajkH9vtFrqMDAD58wZ-BCaU3JJxVhXglB2hKaMURqJWMrjg32C5iG8E0Io5TKT_BRNWJYmcSqTKVoXG8BLa8H0ATuLC7etjW7wq-6MawdTd9h1OIcAndkM7aise2jxApomXOPcecC5HvCz6_EdjN334M_QidVNgPnvnKHiflksHqPVy8PT4nYVGZ7wPuKciDTjJmFGAmOEMVFWmmiQcSViUbHU2thoqyvLsgRIyQwTkJaiApOais_QzS52-1G2UBnoeq8btfV1q_2gnK7Vf6WrN-rNfao45qkU2RhwsQsw3oXgwe5vKVE_XNU319F3fvho7_qjyL8AYCxyiQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chu, Stacey ; Chen, Nita ; Dang, Alexis B C ; Kuo, Alfred C ; Dang, Alan B C</creator><creatorcontrib>Chu, Stacey ; Chen, Nita ; Dang, Alexis B C ; Kuo, Alfred C ; Dang, Alan B C</creatorcontrib><description>The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p&lt;0.0001), 24.82% at 6400 μg/mL (p&lt;0.0001) and 51.83% at 12800 μg/mL of vancomycin (p&lt;0.0001) in comparison to the control group containing no vancomycin. Our in vitro study suggests that vancomycin has toxic effects on hMSCs, a cell population particularly important for bone formation. In the absence of any clinical evidence suggesting that "more vancomycin is better," and our data suggesting that more vancomycin is harmful in vitro, surgeons electing to use topical vancomycin in spine surgery should restrict their use to the doses currently reported in the available published studies unless specific reasons exist otherwise. This study does not establish a contraindication to the use of topical vancomycin, nor does it suggest that pseudarthroses are attributable to vancomycin use.</description><identifier>ISSN: 2211-4599</identifier><identifier>EISSN: 2211-4599</identifier><identifier>DOI: 10.14444/4012</identifier><identifier>PMID: 28765796</identifier><language>eng</language><publisher>Netherlands: International Society for the Advancement of Spine Surgery</publisher><ispartof>International journal of spine surgery, 2017-01, Vol.11 (2), p.12</ispartof><rights>Copyright © 2017 ISASS - This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-3304783c62c9e220224bda0ae95d454d27ff5cafadf286e0b2c24e7b4dec7cd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537948/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537948/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28765796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Stacey</creatorcontrib><creatorcontrib>Chen, Nita</creatorcontrib><creatorcontrib>Dang, Alexis B C</creatorcontrib><creatorcontrib>Kuo, Alfred C</creatorcontrib><creatorcontrib>Dang, Alan B C</creatorcontrib><title>The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better</title><title>International journal of spine surgery</title><addtitle>Int J Spine Surg</addtitle><description>The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p&lt;0.0001), 24.82% at 6400 μg/mL (p&lt;0.0001) and 51.83% at 12800 μg/mL of vancomycin (p&lt;0.0001) in comparison to the control group containing no vancomycin. Our in vitro study suggests that vancomycin has toxic effects on hMSCs, a cell population particularly important for bone formation. In the absence of any clinical evidence suggesting that "more vancomycin is better," and our data suggesting that more vancomycin is harmful in vitro, surgeons electing to use topical vancomycin in spine surgery should restrict their use to the doses currently reported in the available published studies unless specific reasons exist otherwise. This study does not establish a contraindication to the use of topical vancomycin, nor does it suggest that pseudarthroses are attributable to vancomycin use.</description><issn>2211-4599</issn><issn>2211-4599</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkFtLw0AQhRdRbKn9C7IvPkb3lsv6IGipF2j0ocHXZbOZtZEkW3ajkH9vtFrqMDAD58wZ-BCaU3JJxVhXglB2hKaMURqJWMrjg32C5iG8E0Io5TKT_BRNWJYmcSqTKVoXG8BLa8H0ATuLC7etjW7wq-6MawdTd9h1OIcAndkM7aise2jxApomXOPcecC5HvCz6_EdjN334M_QidVNgPnvnKHiflksHqPVy8PT4nYVGZ7wPuKciDTjJmFGAmOEMVFWmmiQcSViUbHU2thoqyvLsgRIyQwTkJaiApOais_QzS52-1G2UBnoeq8btfV1q_2gnK7Vf6WrN-rNfao45qkU2RhwsQsw3oXgwe5vKVE_XNU319F3fvho7_qjyL8AYCxyiQ</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Chu, Stacey</creator><creator>Chen, Nita</creator><creator>Dang, Alexis B C</creator><creator>Kuo, Alfred C</creator><creator>Dang, Alan B C</creator><general>International Society for the Advancement of Spine Surgery</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better</title><author>Chu, Stacey ; Chen, Nita ; Dang, Alexis B C ; Kuo, Alfred C ; Dang, Alan B C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-3304783c62c9e220224bda0ae95d454d27ff5cafadf286e0b2c24e7b4dec7cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Stacey</creatorcontrib><creatorcontrib>Chen, Nita</creatorcontrib><creatorcontrib>Dang, Alexis B C</creatorcontrib><creatorcontrib>Kuo, Alfred C</creatorcontrib><creatorcontrib>Dang, Alan B C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of spine surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Stacey</au><au>Chen, Nita</au><au>Dang, Alexis B C</au><au>Kuo, Alfred C</au><au>Dang, Alan B C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better</atitle><jtitle>International journal of spine surgery</jtitle><addtitle>Int J Spine Surg</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>11</volume><issue>2</issue><spage>12</spage><pages>12-</pages><issn>2211-4599</issn><eissn>2211-4599</eissn><abstract>The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p&lt;0.0001), 24.82% at 6400 μg/mL (p&lt;0.0001) and 51.83% at 12800 μg/mL of vancomycin (p&lt;0.0001) in comparison to the control group containing no vancomycin. Our in vitro study suggests that vancomycin has toxic effects on hMSCs, a cell population particularly important for bone formation. In the absence of any clinical evidence suggesting that "more vancomycin is better," and our data suggesting that more vancomycin is harmful in vitro, surgeons electing to use topical vancomycin in spine surgery should restrict their use to the doses currently reported in the available published studies unless specific reasons exist otherwise. This study does not establish a contraindication to the use of topical vancomycin, nor does it suggest that pseudarthroses are attributable to vancomycin use.</abstract><cop>Netherlands</cop><pub>International Society for the Advancement of Spine Surgery</pub><pmid>28765796</pmid><doi>10.14444/4012</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2211-4599
ispartof International journal of spine surgery, 2017-01, Vol.11 (2), p.12
issn 2211-4599
2211-4599
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537948
source PubMed Central; Alma/SFX Local Collection
title The Effects of Topical Vancomycin on Mesenchymal Stem Cells: More May Not Be Better
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T05%3A55%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Topical%20Vancomycin%20on%20Mesenchymal%20Stem%20Cells:%20More%20May%20Not%20Be%20Better&rft.jtitle=International%20journal%20of%20spine%20surgery&rft.au=Chu,%20Stacey&rft.date=2017-01-01&rft.volume=11&rft.issue=2&rft.spage=12&rft.pages=12-&rft.issn=2211-4599&rft.eissn=2211-4599&rft_id=info:doi/10.14444/4012&rft_dat=%3Cpubmed_cross%3E28765796%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28765796&rfr_iscdi=true